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ABSTRACT
Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disorder caused by 
deficiency of alpha-L-iduronidase (IDUA). Limitations such as the need for weekly 
injections, high morbidity and mortality, and high cost of current treatments show 
that new approaches to treat this disease are required. In this study, we aimed to 
correct fibroblasts from a patient with MPS I using non-viral gene therapy. Using a 
plasmid encoding the human IDUA cDNA, we achieved stable high IDUA levels in 
transfected fibroblasts up to 6 months of treatment. These results serve as proof of 
concept that a non-viral approach can correct the enzyme deficiency in cells of patients 
with lysosomal storage disorders, which can be used as a research tool for a series 
of disease aspects. Future studies should focus on showing if this approach can be 
useful in small animals and clinical trials.
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In mucopolysaccharidosis type I (MPS I), the deficiency in alpha-L-iduronidase 
(IDUA) leads to lysosomal accumulation of the glycosaminoglycans (GAGs) 
heparan and dermatan sulfates. Abnormal storage of these GAGs results in 
progressive cellular and multi-organ dysfunction1.
MPS I has multiple clinical presentations. In its most severe form, 
also known as Hurler syndrome, the disease, in the first year of age, is 
characterized by umbilical hernia, hepatosplenomegaly, skeletal abnormalities 
and developmental delay. The signs are progressive and, when untreated, 
typically result in death in the first two decades of life. In its mildest form, 
also known as Scheie syndrome, the disease has its onset in late childhood 
or puberty with slowly progressive skeletal, heart and eye manifestations. 
Intermediate forms (i.e., Hurler-Scheie syndrome) also exist2.
Treatment approaches include hematopoietic stem cell transplantation 
(HSCT) and enzyme replacement therapy (ERT), both with limited effects. 
Despite recent advances, HSCT still presents a significant morbidity and 
mortality risk, and finding compatible donors is difficult. HSCT is also unable 
to halt the progression of skeletal manifestations even in patients with full 
engraftment and, currently, is indicated only to patients with the severe form 
of the disease, under the age of 2-2.5 years3. Conversely, ERT does not 
correct difficult-to-reach organs, such as the brain and the heart valves, and 
also has limited effects on the skeletal system4-6. Hence, novel strategies are 
needed to treat MPS I.
Gene transfer is a promising option, but safety concerns over the use 
of viral vectors are still a major problem, since insertional mutagenesis and 
development of immune response to the virus have already been described7. 
In the present study, we tested a non-viral gene transfer method aimed to 
correct the enzyme deficiency in fibroblasts from patients with MPS I.
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METHODS
For experiments, human skin fibroblasts (SF) were 
obtained from skin biopsies8 in a patient biochemically 
diagnosed with MPS I. The primary SF culture was 
maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) (Invitrogen, Carlsbad, USA) supplemented 
with 10% fetal calf serum (Cultilab, Brazil) at 37 °C in 
the presence of 5% CO2. The day before transfection, 
cells were plated onto 24-well plates at a density 
of 2 × 105 cells/well to reach 90-95% confluence 
(N = 4 or 5 wells/group).
We used the mammalian episomal expression 
vector pREP9, which carries the Epstein-Barr 
Virus replication origin (EBV oriP), the EBNA-1 
gene (EBV nuclear antigen) and also the neomycin 
resistance (neoR) gene (Invitrogen, San Diego, USA) 
as backbone for plasmid construction. The human 
IDUA cDNA was inserted downstream to the Rous 
sarcoma virus (RSV) constitutive promoter as 
described elsewhere9. The resulting plasmid was 
named pRIDUA (Figure 1). DH5α-T1R Escherichia 
coli (Invitrogen, Carlsbad, USA) was transformed 
with pRIDUA using standard procedures10 and the 
plasmid was purified with Qiagen Plasmid Maxi-Prep 
Kit (Qiagen, Valencia, USA).
Transfections were performed using lipofectamine 
2000 reagent (Invitrogen, Carlsbad, USA) in 
serum-free DMEM for 24 h according to Balestrin et al.11 
or naked DNA. The amounts of lipofectamine used 
were 4 µL for 1.5 µg plasmid in 95% confluent cells plated 
onto 24-well plates (approximately 2 x 105 cells/well). 
Every 4 days medium was changed and supplemented 
with geneticin (400 mg/mL) for two weeks for cloning 
selection. After this period, clones were maintained 
with 200 mg/mL of geneticin.
Alpha-L-iduronidase activity in the cells was 
assessed with a fluorimetric assay that uses 
4-methylumbelliferyl-alpha-L-iduronide (Glycosynth, 
UK) as substrate. Protein content was measured 
using the Lowry method. Results were expressed as 
nmol/h/mg protein12. Comparisons between groups 
were performed using one-way analysis of variance 
(ANOVA) and Tukey’s test for multiple comparisons. 
A p < 0.05 was considered statistically significant.
Fibroblasts from patients with MPS I were submitted 
to transfection with pRIDUA alone or combined with 
lipofectamine, and 24 hours later geneticin selection 
was initiated. We were able to observe clusters of 
cells after 2 weeks only in the plates transfected 
with lipofectamine. No clones were obtained using 
naked DNA.
RESULTS
Enzyme activity in pRIDUA transfected cells reached 
high levels, even higher than reference values for 
normal fibroblasts. The activity observed at 30 days 
was statistically significant compared to untreated 
MPS I fibroblasts (p < 0.05). This increase in enzyme 
activity was maintained along 60, 120 and 180 days 
of experiment (Figure 2). As an additional control to 
verify if the high IDUA levels observed were not due 
to geneticin or the pREP9 plasmid, we determined 
enzyme activity in cells transfected with pREP9 alone 
(without IDUA cDNA) and selected with antibiotics, 
and no increase in IDUA activity was observed (data 
not shown).
Figure 2: IDUA levels in MPS I fibroblasts before 
and after gene transfer. a) Statistically significant 
compared to untreated cells. IDUA reference values 
for normal fibroblasts are 73-150 nmol/h/mg protein. 
IDUA = alpha-L-iduronidase; d = days.
Figure 1: Structure of the pREP9-derived plasmid, pRIDUA. 
Ampicillin = ampicillin resistance gene (complementary 
strand); EBNA-1 = Epstein-Barr virus nuclear antigen gene; 
IDUA = human alpha-L-iduronidase gene; NeoR = neomycin 
resistance gene (complementary strand); OriP = Epstein-Barr 
virus replication origin; PSRV = Rous sarcoma virus long 
terminal repeat promoter; pUC ori = pUC origin of replication; 
PTK = thymidine kinase promoter; SV40pA = simian 
virus 40 polyadenylation signal; TKpA = thymidine kinase 
polyadenylation signal.
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DISCUSSION
The inability of current therapeutic options to 
correct some aspects of MPS I has led researchers 
to develop several new approaches, including new 
delivery routes for ERT13, fusion proteins14, read-through 
compounds15-17, and inhibitors of GAG synthesis18.
The administration of the enzyme by the intrathecal 
route allows it to reach the cerebrospinal fluid directly, 
from where it can go to the brain parenchyma 
through the ependymal layer. Fusion proteins allow 
a therapeutic enzyme to cross the blood-brain barrier 
through receptor-mediated transcytosis. Read-through 
are compounds that allow the translation of a full 
protein in the presence of a premature stop codon 
and are being investigated in the subset of patients 
with MPS I with at least one nonsense mutation 
(e.g., p.Trp402Ter and p.Gln70Ter). Genistein is a 
soy isoflavone used to decrease the GAG synthesis 
and is currently being studied in patients with MPS 
III. It is still not clear if any of these approaches will 
benefit patients with MPS.
Gene therapy is a promising approach to treat 
lysosomal storage disorders such as MPS I. Attempts 
to correct IDUA deficiency have shown interesting 
results in mice and dogs with MPS I19,20. However, most 
of the studies have used viral vectors to deliver cDNA, 
and safety issues such as insertional mutagenesis 
and development of an immune response have been 
raised for different types of viral vectors7,21.
Non-viral gene delivery approaches are a safer 
option; however, they were ignored for a long time, 
until it was demonstrated that they are also able to 
provide long-term transgene expression22.
Here, a single transfection procedure followed by 
antibiotics selection was able to produce stable high 
enzyme levels for up to 6 months. This approach, 
using a pREP9-derived construction, which is an 
episomal vector capable of autonomous replication 
independent of the genome of recipient cells23, could 
be used to transfect other types of cells, such as 
mesenchymal or hematopoietic stem cells, which 
could then be re-infused into the patient, allowing 
a new therapeutic approach for MPS I. However, it 
is important to note that it is still uncertain whether 
gene expression would be maintained in vivo, since 
loss of plasmid and gene silencing can occur24,25. 
Besides, as shown by previous studies on non-viral 
gene therapy in MPS I animal models25,26, immune 
responses are still expected to occur, and an 
immunomodulatory strategy is likely to be required 
in vivo. Still, non-viral gene therapy protocols such 
as the one tested here are cheaper and safer than 
viral vectors, which favors our approach.
In the present study, we showed that non-viral ex-
vivo gene therapy in human MPS I cells is feasible 
and long-term correction can be obtained. Future 
studies on the clinical application of such approach 
shall be conducted to obtain data on safety and 
efficacy of this procedure.
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